Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cancer immunotherapy drug shrink rare sarcomas?

NCT ID NCT04458922

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This phase 2 trial tests the drug atezolizumab in 27 people with chondrosarcoma or clear cell sarcoma that cannot be removed by surgery or has spread. Atezolizumab is an immunotherapy that helps the body's immune system attack cancer cells. The main goal is to see if the drug can shrink tumors or slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Atezolizumab (a drug that helps the immune system attack cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for rare sarcomas that cannot be surgically removed.
What could go wrong
This is a small, early-phase trial with only 27 participants. The drug may not shrink tumors or improve survival, and side effects from immune activation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL CHONDROSARCOMA, GRADE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chondrosarcoma clear cell sarcoma dedifferentiated chondrosarcoma follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL CHONDROSARCOMA, GRADE 2 CENTRAL CHONDROSARCOMA, GRADE 3 DEDIFFERENTIATED CHONDROSARCOMA METASTATIC CLEAR CELL SARCOMA OF SOFT TISSUE METASTATIC PRIMARY CENTRAL CHONDROSARCOMA UNRESECTABLE PRIMARY CENTRAL CHONDROSARCOMA

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Emory University Hospital Midtown

    Atlanta, Georgia, 30308, United States

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • NCI - Center for Cancer Research

    Bethesda, Maryland, 20892, United States

  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda, Maryland, 20892, United States

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Siteman Cancer Center-South County

    St Louis, Missouri, 63129, United States

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida, 32610, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • UT MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • University Health Network-Princess Margaret Hospital

    Toronto, Ontario, M5G 2M9, Canada

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.